Anavex Life Sciences Corp.
(NASDAQ : AVXL)

( )
AVXL After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -5.06%150.000.0%$678.53m
AMGNAmgen, Inc. -0.35%249.701.4%$585.90m
GILDGilead Sciences, Inc. -1.27%65.181.0%$429.55m
VRTXVertex Pharmaceuticals, Inc. -1.65%294.291.9%$402.50m
REGNRegeneron Pharmaceuticals, Inc. -1.81%624.832.6%$354.90m
ILMNIllumina, Inc. -1.86%209.063.3%$307.20m
SNSSSunesis Pharmaceuticals, Inc. 2.22%4.150.7%$290.10m
NVAXNovavax, Inc. -5.56%37.1875.7%$231.38m
BIIBBiogen, Inc. -0.57%216.341.8%$185.52m
BNTXBioNTech SE -2.91%147.610.0%$150.86m
SAVACassava Sciences, Inc. 2.92%26.470.0%$120.22m
GOVXGeoVax Labs, Inc. -12.83%1.970.0%$104.86m
BMRNBioMarin Pharmaceutical, Inc. -1.98%92.964.2%$97.95m
CRSPCRISPR Therapeutics AG 0.57%72.150.6%$91.12m
EXASEXACT Sciences Corp. -2.73%38.4817.6%$84.05m

Company Profile

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.